189 related articles for article (PubMed ID: 38778353)
1. Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly.
Niimi Y; Janelidze S; Sato K; Tomita N; Tsukamoto T; Kato T; Yoshiyama K; Kowa H; Iwata A; Ihara R; Suzuki K; Kasuga K; Ikeuchi T; Ishii K; Ito K; Nakamura A; Senda M; Day TA; Burnham SC; Iaccarino L; Pontecorvo MJ; Hansson O; Iwatsubo T
Alzheimers Res Ther; 2024 May; 16(1):115. PubMed ID: 38778353
[TBL] [Abstract][Full Text] [Related]
2. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
[TBL] [Abstract][Full Text] [Related]
3. Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease.
Janelidze S; Berron D; Smith R; Strandberg O; Proctor NK; Dage JL; Stomrud E; Palmqvist S; Mattsson-Carlgren N; Hansson O
JAMA Neurol; 2021 Feb; 78(2):149-156. PubMed ID: 33165506
[TBL] [Abstract][Full Text] [Related]
4. Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tau.
Janelidze S; Palmqvist S; Leuzy A; Stomrud E; Verberk IMW; Zetterberg H; Ashton NJ; Pesini P; Sarasa L; Allué JA; Teunissen CE; Dage JL; Blennow K; Mattsson-Carlgren N; Hansson O
Alzheimers Dement; 2022 Feb; 18(2):283-293. PubMed ID: 34151519
[TBL] [Abstract][Full Text] [Related]
5. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.
Thijssen EH; La Joie R; Strom A; Fonseca C; Iaccarino L; Wolf A; Spina S; Allen IE; Cobigo Y; Heuer H; VandeVrede L; Proctor NK; Lago AL; Baker S; Sivasankaran R; Kieloch A; Kinhikar A; Yu L; Valentin MA; Jeromin A; Zetterberg H; Hansson O; Mattsson-Carlgren N; Graham D; Blennow K; Kramer JH; Grinberg LT; Seeley WW; Rosen H; Boeve BF; Miller BL; Teunissen CE; Rabinovici GD; Rojas JC; Dage JL; Boxer AL;
Lancet Neurol; 2021 Sep; 20(9):739-752. PubMed ID: 34418401
[TBL] [Abstract][Full Text] [Related]
6. Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers.
Mattsson-Carlgren N; Salvadó G; Ashton NJ; Tideman P; Stomrud E; Zetterberg H; Ossenkoppele R; Betthauser TJ; Cody KA; Jonaitis EM; Langhough R; Palmqvist S; Blennow K; Janelidze S; Johnson SC; Hansson O
JAMA Neurol; 2023 Apr; 80(4):360-369. PubMed ID: 36745413
[TBL] [Abstract][Full Text] [Related]
7. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.
Palmqvist S; Janelidze S; Quiroz YT; Zetterberg H; Lopera F; Stomrud E; Su Y; Chen Y; Serrano GE; Leuzy A; Mattsson-Carlgren N; Strandberg O; Smith R; Villegas A; Sepulveda-Falla D; Chai X; Proctor NK; Beach TG; Blennow K; Dage JL; Reiman EM; Hansson O
JAMA; 2020 Aug; 324(8):772-781. PubMed ID: 32722745
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology.
Ashton NJ; Brum WS; Di Molfetta G; Benedet AL; Arslan B; Jonaitis E; Langhough RE; Cody K; Wilson R; Carlsson CM; Vanmechelen E; Montoliu-Gaya L; Lantero-Rodriguez J; Rahmouni N; Tissot C; Stevenson J; Servaes S; Therriault J; Pascoal T; Lleó A; Alcolea D; Fortea J; Rosa-Neto P; Johnson S; Jeromin A; Blennow K; Zetterberg H
JAMA Neurol; 2024 Mar; 81(3):255-263. PubMed ID: 38252443
[TBL] [Abstract][Full Text] [Related]
9. Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease.
Janelidze S; Teunissen CE; Zetterberg H; Allué JA; Sarasa L; Eichenlaub U; Bittner T; Ovod V; Verberk IMW; Toba K; Nakamura A; Bateman RJ; Blennow K; Hansson O
JAMA Neurol; 2021 Nov; 78(11):1375-1382. PubMed ID: 34542571
[TBL] [Abstract][Full Text] [Related]
10. Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers.
Janelidze S; Christian BT; Price J; Laymon C; Schupf N; Klunk WE; Lott I; Silverman W; Rosas HD; Zaman S; Mapstone M; Lai F; Ances BM; Handen BL; Hansson O
JAMA Neurol; 2022 Aug; 79(8):797-807. PubMed ID: 35789365
[TBL] [Abstract][Full Text] [Related]
11. Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study.
Pérez-Grijalba V; Arbizu J; Romero J; Prieto E; Pesini P; Sarasa L; Guillen F; Monleón I; San-José I; Martínez-Lage P; Munuera J; Hernández I; Buendía M; Sotolongo-Grau O; Alegret M; Ruiz A; Tárraga L; Boada M; Sarasa M;
Alzheimers Res Ther; 2019 Dec; 11(1):96. PubMed ID: 31787105
[TBL] [Abstract][Full Text] [Related]
12. Effects of certain pre-analytical factors on the performance of plasma phospho-tau217.
Bali D; Hansson O; Janelidze S
Alzheimers Res Ther; 2024 Feb; 16(1):31. PubMed ID: 38331843
[TBL] [Abstract][Full Text] [Related]
13. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.
Palmqvist S; Zetterberg H; Blennow K; Vestberg S; Andreasson U; Brooks DJ; Owenius R; Hägerström D; Wollmer P; Minthon L; Hansson O
JAMA Neurol; 2014 Oct; 71(10):1282-9. PubMed ID: 25155658
[TBL] [Abstract][Full Text] [Related]
14. Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease.
Rissman RA; Langford O; Raman R; Donohue MC; Abdel-Latif S; Meyer MR; Wente-Roth T; Kirmess KM; Ngolab J; Winston CN; Jimenez-Maggiora G; Rafii MS; Sachdev P; West T; Yarasheski KE; Braunstein JB; Irizarry M; Johnson KA; Aisen PS; Sperling RA;
Alzheimers Dement; 2024 Feb; 20(2):1214-1224. PubMed ID: 37932961
[TBL] [Abstract][Full Text] [Related]
15. Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies.
Mattsson-Carlgren N; Collij LE; Stomrud E; Pichet Binette A; Ossenkoppele R; Smith R; Karlsson L; Lantero-Rodriguez J; Snellman A; Strandberg O; Palmqvist S; Ashton NJ; Blennow K; Janelidze S; Hansson O
JAMA Neurol; 2024 Jan; 81(1):69-78. PubMed ID: 38048096
[TBL] [Abstract][Full Text] [Related]
16. The Bio-Hermes Study: Biomarker database developed to investigate blood-based and digital biomarkers in community-based, diverse populations clinically screened for Alzheimer's disease.
Mohs RC; Beauregard D; Dwyer J; Gaudioso J; Bork J; MaGee-Rodgers T; Key MN; Kerwin DR; Hughes L; Cordell CB;
Alzheimers Dement; 2024 Apr; 20(4):2752-2765. PubMed ID: 38415908
[TBL] [Abstract][Full Text] [Related]
17. Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures.
Palmqvist S; Tideman P; Cullen N; Zetterberg H; Blennow K; ; Dage JL; Stomrud E; Janelidze S; Mattsson-Carlgren N; Hansson O
Nat Med; 2021 Jun; 27(6):1034-1042. PubMed ID: 34031605
[TBL] [Abstract][Full Text] [Related]
18. Predictive Accuracy of Blood-Derived Biomarkers for Amyloid-β Brain Deposition Along with the Alzheimer's Disease Continuum: A Systematic Review.
Cianflone A; Coppola L; Mirabelli P; Salvatore M
J Alzheimers Dis; 2021; 84(1):393-407. PubMed ID: 34542072
[TBL] [Abstract][Full Text] [Related]
19. Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early stage Alzheimer's disease.
Lin SY; Lin KJ; Lin PC; Huang CC; Chang CC; Lee YC; Hsiao IT; Yen TC; Huang WS; Yang BH; Wang PN
Alzheimers Res Ther; 2019 Dec; 11(1):111. PubMed ID: 31881963
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease.
Mattsson-Carlgren N; Janelidze S; Palmqvist S; Cullen N; Svenningsson AL; Strandberg O; Mengel D; Walsh DM; Stomrud E; Dage JL; Hansson O
Brain; 2020 Dec; 143(11):3234-3241. PubMed ID: 33068398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
